Clinomics to be Acquired by Cytomyx of London
Clinomics Biosciences, of Frederick, Md., has agreed to be acquired by Cytomyx Holdings of London, the company said this week.
Clinomics provides gene expression services, and has developed tissue microarrays that contain hundreds of tissue samples arrayed on a slide.
The merger agreement, which is conditional and awaits regulatory approval, is designed to increase the market distribution leverage of Clinomics and Cytomyx, which also makes drug discovery tools, said Steve Turner, Clinomics’ CEO.
“Cytomyx has been building a portfolio of drug discovery related products over the past two years and our link with them will enable us to integrate our products and services to increase our overall market position,” Turner said in a statement. “We plan to build a US-based sales force both for Clinomics’ existing products and for Cytomyx’s new product lines.”
US Military Pathology Institute Selects Third Wave’s CF ASRs
The US Armed Forces Institute of Pathology (AFIP) — the central reference laboratory for the Army, Navy, Air Force, Public Health Service, and Department of Veterans Affairs — has selected Third Wave Technologies’ Invader analyte-specific reagents for cystic fibrosis (CF) genetic screening, the company said last week.
AFIP will use the Invader ASRs to screen US military personnel for genetic mutations associated with CF to determine whether those individuals are carriers for the disease.
“We expect the number of [CF] test requests to double or triple as more and more Army facilities seek out our expertise,” Jack Lichy, director of the AFIP Molecular Diagnostics Laboratory, said in a statement.
Roche Diagnostics In Agreement with Kansas City Clinical Lab for Molecular Dx
Saint Luke’s Health System, a Kansas City-based provider of molecular diagnostics and clinical testing, said last week that it has signed a five-year strategic alliance agreement with Roche Diagnostics to establish a Molecular Center of Excellence to perform molecular diagnostic testing using Roche’s PCR technology and other genomic technologies.
Financial terms of the agreement were not provided.
According to Saint Luke’s Health System, molecular diagnostic testing will improve its diagnostic services “by providing more sensitive, more specific, and faster results so that patient treatment can be improved.” Molecular testing should be able to measure the amount of a pathogen present in the system, allowing better treatment options, and will also provide accurate negative-predictive values when screening for genetic mutations in cystic fibrosis and other diseases, Saint Luke’s said.
Qiagen to Integrate Nucleic Acid Sample Prep Products with Artus Dx Systems
Qiagen’s German subsidiary has entered into a manufacturing and supply deal with Artus, of Hamburg, Germany in which Artus will integrate Qiagen’s nucleic acid sample preparation products into its infectious disease diagnostic systems, the companies said today.
Under the agreement, Artus will use versions of Qiagen’s QiAmp technology in its custom diagnostic tooks, which include systems for detection of diseases such as SARS, herpes simplex virus -1/-2, EBV, West Nile virus, malaria, and salmonella. The systems use Artus’ RealArt technology, which is based on PCR technology that Artus has licensed from Roche, according to the companies.
The companies did not disclose the financial terms of the agreement.
Sequenom Inks Gene Expression Deals with TIGR, U. Michigan
Sequenom said this week that it had penned agreements with the Institute for Genomic Research in Rockville, Md., and the University of Michigan Medical Center, in Ann Arbor, Mich., for its gene expression analysis technology.
TIGR is using the technology, which runs on Sequenom’s MassArray Compact System, to study the way genetic polymorphisms functionally impact gene expression, the San Diego-based company said.
The University of Michigan Medical Center has purchased Sequenom’s MassArray 7K system, which is designed to enable quantitative detection of low-copy number genes. The pediatrics and human genetics department, which conducts research on genetic diseases affecting children, is using this system, according to Sequenom.
The parties did not disclose the financial terms of the agreement.